First-line fulvestrant plus anastrozole for hormone-receptor-positive metastatic breast cancer in postmenopausal women: a cost-effectiveness analysis

被引：0
|
作者：
Weiting Liao
Jiaxing Huang
Qiuji Wu
Feng Wen
Nan Zhang
Kexun Zhou
Liangliang Bai
Qiu Li
机构：
[1] Sichuan University,Department of Medical Oncology, Cancer Center, West China Hospital
[2] Sichuan University,West China Biomedical Big Data Center
来源：
Breast Cancer | 2020年 / 27卷
关键词：
Cost-effectiveness analysis; Breast cancer; Hormone-receptor-positive; Fulvestrant; Anastrozole; Dual endocrine therapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：399 / 404
页数：5
相关论文
共 50 条
  • [21] Anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer: A meta-analysis.
    Tan, Pui San
    Haaland, Benjamin
    Montero, Alberto J.
    Lopes, Gilberto
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer
    Pui San Tan
    Haaland, Benjamin
    Montero, Alberto J.
    Lopes, Gilberto
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 138 (03) : 961 - 965
  • [23] A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer
    Pui San Tan
    Benjamin Haaland
    Alberto J. Montero
    Gilberto Lopes
    Breast Cancer Research and Treatment, 2013, 138 : 961 - 965
  • [24] A Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Postmenopausal Women with Metastatic Breast Cancer: SWOG S0226
    Mehta, R. S.
    Barlow, W. E.
    Albam, K. S.
    Vandenberg, T.
    Dakhil, S. R.
    Tirumali, N. R.
    Lew, D. L.
    Hayes, D. F.
    Gralow, J. R.
    Livingston, R. B.
    Hortobagyi, G. N.
    CANCER RESEARCH, 2011, 71
  • [25] Cost-Effectiveness Analysis of Abemaciclib plus Fulvestrant versus Placebo plus Fulvestrant in Patients with Hormone Receptor-Positive, ERBB2-Negative Breast Cancer
    Xie, Qian
    Zheng, Hanrui
    Li, Qiu
    BREAST CARE, 2022, 17 (03) : 237 - 242
  • [26] Cost-effectiveness analysis of ribociclib plus fulvestrant for hormone receptor-positive/human EGF receptor 2-negative breast cancer
    Jiang, Wei
    He, Zhichao
    Zhang, Tiantian
    Guo, Chongchong
    Zhao, Jianli
    Zhu, Jianhong
    Wu, Junyan
    Yu, Xiaoxia
    Chen, Chuxiong
    Li, Jianfang
    Jiang, Jie
    IMMUNOTHERAPY, 2021, 13 (08) : 661 - 668
  • [27] Cost-Effectiveness Analysis of Fulvestrant 500 mg in Endocrine Therapy-Naive Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer in the UK
    Telford, Claire
    Bertranou, Evelina
    Large, Samuel
    Phelps, Hilary
    Ekman, Mattias
    Livings, Christopher
    PHARMACOECONOMICS-OPEN, 2019, 3 (04) : 559 - 570
  • [28] Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer
    Pei, Zhengda
    Xiao, Ningping
    Yang, Pei
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [29] Results of the randomized phase II trial of adjuvant anastrozole versus anastrozole plus fulvestrant in hormone-receptor-positive postmenopausal breast cancer patients with bone marrow micrometastasis (ABCSG trial 21).
    Braun, S.
    Naume, B.
    Mueller, E.
    Janni, W.
    Marth, C.
    Gnant, M. F.
    CANCER RESEARCH, 2009, 69 (02) : 297S - 298S
  • [30] A phase III randomized trial of anastrozole and fulvestrant versus anastrozole or sequential anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer: Final survival outcomes of SWOG S0226
    Mehta, Rita S.
    Barlow, William E.
    Albain, Kathy S.
    Vandenberg, Ted A.
    Dakhil, Shakher R.
    Tirumali, Nagendra L.
    Lew, Danika L.
    Hayes, Daniel F.
    Gralow, Julie R.
    Linden, Hannah M.
    Livingston, Robert B.
    Hortobagyi, Gabriel N.
    CANCER RESEARCH, 2018, 78 (04)
12345